Latest News

The Weight Loss Revolution: Hype or Healthcare Shift?
Merill SICAV - 27.09.2023

The world of healthcare investment is changing because of exciting new developments in weight-loss medication, driven by groundbreaking drugs like Wegovy from Novo Nordisk. These medications not only aid weight loss but also reduce the risk of heart attacks and strokes by about 20%, reshaping investment trends in healthcare.

In our recent episode of Merill Talks, we have Marc Ellazidi, CIO at JMFA, and journalist Yannick Pace, talking about the innovative solutions from Novo Nordisk and Eli Lilly. They break down how these developments are affecting the market and point out some promising investment opportunities. This video is an extension of our article in the Sunday Times from August, giving you a closer look at the topic:

The Weight Loss Revolution: Hype or Healthcare Shift?

< Back to Latest News